Andrew C. Jackson - 21 Aug 2025 Form 4 Insider Report for Calidi Biotherapeutics, Inc. (CLDI)

Role
Chief Financial Officer
Signature
/s/ Andrew Jackson
Issuer symbol
CLDI
Transactions as of
21 Aug 2025
Net transactions value
+$5,000
Form type
4
Filing time
25 Aug 2025, 20:47:36 UTC
Previous filing
20 Jun 2024
Next filing
05 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Jackson Andrew C. Chief Financial Officer C/O CALIDI BIOTHERAPEUTICS, INC., 4475 EXECUTIVE DRIVE, SUITE 200, SAN DIEGO, /s/ Andrew Jackson 25 Aug 2025 0001636738

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLDI Common Stock Purchase $5,000 +2,500 $2.00* 2,500 21 Aug 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDI Warrant (right to buy) Purchase +2,500 2,500 21 Aug 2025 Common stock 2,500 $2.00 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The common stock and warrants were acquired by the reporting person in a public offering conducted by the Issuer that was closed on August 21, 2025.
F2 Each common share was purchased with an accompanying warrant for a purchase price of $2.00 per share and accompanying warrant.